Chronic HCV Infection in HIV-Positive Patients: A New Challenge

Soriano V , Sulkowski M , Bergin C , et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 2002;16(6):813-828.

Bica I , McGovern B , Dhar R , et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32(3): 492-497.

Cacoub P , Geffray L , Rosenthal E , et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32(8):1207-1214.

Lauer GM , Walker BD . Hepatitis C virus infection. N Engl J Med 2001; 345(1):41-52.

Pol S , Lamorthe B , Thi NT , et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998; 28(6): 945-950.

Soto B , Sánchez-Quijano A , Rodrigo L , del Olmo JA , et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26(1):1-5.

Benhamou Y , Bochet M , Di Martino V , et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30(4):1054-1058.

García-Samaniego J , Rodríguez M , Berenguer J , et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96(1):179-183.

Poynard T , Mathurin P , Lai CL , et al. (The PANFIBROSIS Group). A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38(3):257-265.

Graham CS , Baden LR , Yu E , et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33(4): 562-569.

Sulkowski MS , Thomas DL , Chaisson RE , Moore RD . Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283(1):74-80.

Benhamou Y , Di Martino V , Bochet M , et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001; 34(2):283-287.

Tural C , Fuster D , Tor J , et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10(2):118-125.

Di Martino V , Rufat P , Boyer N , et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001; 34(6):1193-1199.

Kontorinis N , Dieterich D . Hepatotoxicity of Antiretroviral Therapy. AIDS Reviews 2003; 5(1):36-43.

Greub G , Ledergerber B , Battegay M , et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss Cohort Study. Lancet 2000; 356(9244):1800-1805.

De Luca A , Bugarini R , Lepri AC , et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162 (18):2125-2132.

Sulkowski MS , Moore RD , Mehta SH , et al. Hepatitis C and progression of HIV disease. JAMA 2002; 288(2):199-206.

Rancinan C , Neau D , Savès M , et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16(10):1357-1362.

Perez-Olmeda M , Nunez M , Romero M , et al. Pegylated IFN-alfa2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17(7):1023-1028.

Chung R , Anderson J , Alston B , et al. A randomised, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071. 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002. Seattle, WA. (Abstract LB15).

Ballesteros AL , Tural C , Fuster D , et al. Safety of peg-interferon (Peg-IFN) and ribavirin (RBV) for chronic hepatitis C (HCV) in HIV-infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27-30, 2002. San Diego, CA. (Abstract V-685).

Lafeuillade A , Hittinger G , Chadapaud S . Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357(9252):280-281.

Ballesteros AL , Franco S , Fuster D , et al. Predictive value of early virological reduction (EVR) in the response at 24 weeks (W) of HCV treatment with peg-interferon (Peg-IFN) & ribavirine (RBV) in HIV-infected patients (P). 38th European Asssociation for the Study of the Liver (EASL) Conference. March 29-April 1, 2003. Istanbul, Turkey. (Cancelled due to war in Iraq). Accessed June 1, 2003 at: http://www.hcvadvocate.org/EASL-HCV.htm

Myers RP , Benhamou Y , Imbert-Bismut F , et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17(5):721-725.

Soriano V , Martín-Carbonero L , García-Samaniego J . Treatment of chronic hepatitis C virus infection: We must target the virus or liver fibrosis? AIDS 2003; 17(5):751-753.

Gow PJ , Pillay D , Mutimer D . Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72(2):177-181.